Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 2, 2014

Bristol-Myers Squibb expands biologics manufacturing agreement with Lonza

Bristol-Myers Squibb (BMS) has expanded its existing biologics manufacturing agreement with Switzerland-based Lonza.

Myer

Bristol-Myers Squibb (BMS) has expanded its existing biologics manufacturing agreement with Switzerland-based Lonza.

The contract is expanded for the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire.

Terms of the transaction were not disclosed.

Bristol-Myers Squibb global manufacturing and supply president Lou Schmukler said: "Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio, and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities."

Both companies partnered in 2003 to produce commercial supplies of a biologics medicine marketed by BMS across the globe.

"According to BMS, the biologic medicines that treat serious diseases are an integral part of its specialty care portfolio and R&D pipeline."

According to BMS, the biologic medicines that treat serious diseases are an integral part of its specialty care portfolio and R&D pipeline. Lonza also manufactures clinical supplies of an investigational biologics medicine for BMS.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Lonza pharma and biotech segment chief operating officer (COO) Marc Funk said: "We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug substance.

"This reinforces Lonza’s mission to support life-saving medicines by being a reliable supplier of drug substances for our customers with high-quality commercial GMP manufacturing services delivered to the market."

Lonza’s additional clinical-to-commercial mammalian production facilities are in Tuas in Singapore, Porrino in Spain and Slough in the UK, as well as its Portsmouth facility.


Image: Entrance to the Bristol-Myers Squibb site at Reeds Lane, Moreton, Wirral, England. Photo: courtesy of Rept0n1x.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU